Free Trial

Rapport Therapeutics (RAPP) Competitors

Rapport Therapeutics logo
$16.05 -0.57 (-3.43%)
Closing price 04:00 PM Eastern
Extended Trading
$16.09 +0.04 (+0.25%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RAPP vs. DNLI, BEAM, KNSA, BLTE, CNTA, VCEL, IRON, HRMY, IDYA, and CGON

Should you be buying Rapport Therapeutics stock or one of its competitors? The main competitors of Rapport Therapeutics include Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Kiniksa Pharmaceuticals International (KNSA), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), Vericel (VCEL), Disc Medicine (IRON), Harmony Biosciences (HRMY), IDEAYA Biosciences (IDYA), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry.

Rapport Therapeutics vs. Its Competitors

Rapport Therapeutics (NASDAQ:RAPP) and Denali Therapeutics (NASDAQ:DNLI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

Rapport Therapeutics' return on equity of -25.48% beat Denali Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rapport TherapeuticsN/A -25.48% -24.63%
Denali Therapeutics N/A -35.90%-32.41%

Denali Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rapport TherapeuticsN/AN/A-$78.31M-$3.45-4.65
Denali TherapeuticsN/AN/A-$422.77M-$2.67-5.12

In the previous week, Denali Therapeutics had 3 more articles in the media than Rapport Therapeutics. MarketBeat recorded 4 mentions for Denali Therapeutics and 1 mentions for Rapport Therapeutics. Denali Therapeutics' average media sentiment score of 1.63 beat Rapport Therapeutics' score of 0.94 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Rapport Therapeutics Positive
Denali Therapeutics Very Positive

92.9% of Denali Therapeutics shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Rapport Therapeutics currently has a consensus target price of $28.00, suggesting a potential upside of 74.45%. Denali Therapeutics has a consensus target price of $33.71, suggesting a potential upside of 146.63%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Denali Therapeutics is more favorable than Rapport Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rapport Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Denali Therapeutics
0 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
2 Strong Buy rating(s)
3.06

Summary

Denali Therapeutics beats Rapport Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Rapport Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RAPP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RAPP vs. The Competition

MetricRapport TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$585.83M$3.04B$5.74B$9.51B
Dividend YieldN/A2.40%4.60%3.99%
P/E Ratio-4.6521.1828.1120.03
Price / SalesN/A337.65460.63103.88
Price / CashN/A43.2336.5559.01
Price / Book1.928.368.655.90
Net Income-$78.31M-$55.19M$3.25B$258.66M
7 Day Performance9.33%5.89%4.20%2.23%
1 Month Performance36.83%17.63%10.83%12.77%
1 Year Performance-27.74%5.10%34.67%19.36%

Rapport Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RAPP
Rapport Therapeutics
1.5018 of 5 stars
$16.05
-3.4%
$28.00
+74.5%
-17.8%$585.83MN/A-4.65N/A
DNLI
Denali Therapeutics
4.2552 of 5 stars
$14.69
+1.2%
$33.71
+129.5%
-39.4%$2.13B$330.53M-5.50430News Coverage
Positive News
Upcoming Earnings
BEAM
Beam Therapeutics
2.2175 of 5 stars
$21.17
+0.0%
$48.75
+130.3%
-29.7%$2.13B$63.52M-4.59510Analyst Revision
KNSA
Kiniksa Pharmaceuticals International
3.4535 of 5 stars
$28.80
+2.5%
$39.33
+36.6%
+6.7%$2.10B$423.24M-115.20220News Coverage
BLTE
Belite Bio
1.7942 of 5 stars
$63.58
+0.6%
$96.67
+52.0%
+28.5%$2.02BN/A-46.7510High Trading Volume
CNTA
Centessa Pharmaceuticals
3.3153 of 5 stars
$15.13
+4.9%
$27.89
+84.3%
+51.2%$2.02B$15M-8.36200High Trading Volume
VCEL
Vericel
3.6708 of 5 stars
$39.82
-0.3%
$61.14
+53.5%
-24.2%$2.00B$238.54M1,327.78300News Coverage
Positive News
Upcoming Earnings
IRON
Disc Medicine
3.3594 of 5 stars
$57.74
+1.5%
$96.70
+67.5%
+36.0%$2.00BN/A-14.7330
HRMY
Harmony Biosciences
4.7967 of 5 stars
$34.71
+2.1%
$51.33
+47.9%
+11.9%$1.99B$714.73M13.25200Positive News
Analyst Revision
IDYA
IDEAYA Biosciences
4.1856 of 5 stars
$22.58
+0.4%
$47.55
+110.6%
-41.2%$1.98B$7M-6.2980News Coverage
Analyst Forecast
CGON
CG Oncology
2.236 of 5 stars
$25.90
-3.1%
$56.80
+119.3%
-21.3%$1.97B$1.14M-17.1561

Related Companies and Tools


This page (NASDAQ:RAPP) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners